VCYT Veracyte, Inc. Stock Quote

VCYT [NASD]

Index	-	P/E	-	EPS (ttm)	-0.68	Insider Own	0.90%	Shs Outstand	57.90M	Perf Week	8.05%
Market Cap	3.23B	Forward P/E	-	EPS next Y	-0.30	Insider Trans	-45.34%	Shs Float	57.52M	Perf Month	12.60%
Income	-34.30M	PEG	-	EPS next Q	-0.11	Inst Own	-	Short Float	7.33%	Perf Quarter	31.44%
Sales	112.70M	P/S	28.70	EPS this Y	56.00%	Inst Trans	0.23%	Short Ratio	6.45	Perf Half Y	71.93%
Book/sh	7.71	P/B	7.00	EPS next Y	52.40%	ROA	-11.00%	Target Price	46.20	Perf Year	89.27%
Cash/sh	5.76	P/C	9.37	EPS next 5Y	-	ROE	-12.30%	52W Range	13.90 - 63.55	Perf YTD	10.28%
Dividend	-	P/FCF	-	EPS past 5Y	27.40%	ROI	-6.30%	52W High	-15.07%	Beta	0.72
Dividend %	-	Quick Ratio	26.30	Sales past 5Y	25.80%	Gross Margin	64.20%	52W Low	288.27%	ATR	3.95
Employees	354	Current Ratio	26.60	Sales Q/Q	0.30%	Oper. Margin	-31.60%	RSI (14)	55.92	Volatility	7.97% 7.89%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-400.50%	Profit Margin	-30.50%	Rel Volume	1.17	Prev Close	54.17
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Nov 02 AMC	Payout	-	Avg Volume	653.48K	Price	53.97
Recom	2.00	SMA20	4.54%	SMA50	4.77%	SMA200	51.67%	Volume	766,376	Change	-0.37%

Nov-10-20

Initiated

KeyBanc Capital Markets

Sector Weight

$48

Sep-09-20

Initiated

Morgan Stanley

Underweight

$35

Jul-31-19

Initiated

Lake Street

Buy

$35

Jul-02-19

Initiated

Needham

Buy

$33

Nov-29-18

Downgrade

Janney

Buy → Neutral

Oct-31-18

Upgrade

Janney

Neutral → Buy

Nov-07-17

Downgrade

Piper Jaffray

Overweight → Neutral

Nov-07-17

Downgrade

Janney

Buy → Neutral

Aug-31-17

Resumed

BTIG Research

Buy

$13

Nov-14-16

Resumed

Leerink Partners

Outperform

$12

Dec-18-15

Initiated

Cantor Fitzgerald

Buy

$13

Jun-11-15

Reiterated

Leerink Partners

Outperform

$11 → $13

Nov-26-13

Initiated

William Blair

Outperform

Jan-06-21 02:00PM	Veracyte to Participate in 23rd Annual Needham Virtual Growth Conference Business Wire
Dec-23-20 08:00AM	Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal GlobeNewswire
Dec-22-20 08:52AM	Veracyte (VCYT) in Focus: Stock Moves 7% Higher Zacks +11.46%
08:15AM	Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer Business Wire
Dec-21-20 08:15AM	Veracyte Announces ISO 13485:2016 Certification for Its In Vitro Diagnostics Quality Management System Business Wire +7.01%
Dec-16-20 12:00PM	Veracyte Announces New Preliminary Data for Its In-Development Lung Cancer Portfolio Tests Business Wire -11.67%
Dec-15-20 05:59PM	Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity Business Wire
08:15AM	Veracyte Announces Expansion of Collaboration with the Lung Cancer Initiative at Johnson & Johnson Business Wire
Dec-11-20 10:00PM	Is VCYT A Good Stock To Buy Now? Insider Monkey
Dec-03-20 02:30PM	Veracyte to Host Virtual Lung Cancer R&D Day on Wednesday, December 16, 2020 Business Wire
Nov-23-20 04:05PM	Veracyte to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference Business Wire
Nov-17-20 09:45AM	Veracyte Announces New General Manager Structure to Advance Global Expansion Business Wire
Nov-16-20 03:19PM	What We Know About How Moderna and Pfizer Vaccines Compare Barrons.com
Nov-05-20 03:05AM	Prosigna Breast Cancer Assay Now Approved for Reimbursement in Germany Business Wire
Nov-04-20 12:42PM	Imagine Holding Veracyte (NASDAQ:VCYT) Shares While The Price Zoomed 502% Higher Simply Wall St.
Nov-02-20 06:55PM	Veracyte (VCYT) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:05PM	Veracyte Announces Third Quarter 2020 Financial Results Business Wire
02:30PM	Veracyte, Inc. to Host Earnings Call ACCESSWIRE
Oct-30-20 08:15AM	Veracyte Announces New Data Published in Journal of Clinical Oncology Suggest the Prosigna Breast Cancer Tests Genomic Underpinning Drives Prognostic Performance Business Wire -5.84%
Oct-26-20 12:31PM	Analysts Estimate Veracyte (VCYT) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-22-20 04:05PM	Veracyte Announces Publication of Manuscript Describing Scientific Rigor Behind Next-Generation Percepta Genomic Sequencing Classifier Business Wire
Oct-19-20 08:15AM	Veracyte Announces New Data Reinforcing Foundational Technology of Nasal Swab Test for Early Lung Cancer Detection Presented at CHEST Annual Meeting 2020 Business Wire
Oct-14-20 04:05PM	Veracyte Announces Two Presentations to Be Shared at CHEST Annual Meeting 2020 Business Wire
Oct-07-20 08:15AM	Veracyte to Release Third Quarter 2020 Financial Results on November 2, 2020 Business Wire
Sep-24-20 08:15AM	Veracyte Receives ADLT Status for Envisia Genomic Classifier From Centers for Medicare and Medicaid Services Business Wire
Sep-15-20 04:30PM	Veracyte to Present at Two Investor Conferences Business Wire
Sep-14-20 01:45PM	Veracyte Announces Promotion of Richard T. Kloos, M.D. To Executive Medical Director Business Wire
Sep-11-20 08:15AM	Veracyte Announces Initiation of Consensus Study Exploring Medical Utility of Multiple Breast Cancer Genomic Tests Business Wire
Sep-09-20 09:44AM	Benzinga's Top Upgrades, Downgrades For September 9, 2020 Benzinga
Sep-04-20 08:15AM	Veracyte to Present at Upcoming Investor Conferences Business Wire
Aug-24-20 08:15AM	Veracyte Named a San Francisco Bay Area "Top Workplace" for Seventh Consecutive Year Business Wire -7.98%
Aug-07-20 04:15PM	Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
Aug-05-20 04:15PM	Veracyte Announces New Real-World Data Reinforcing the Potential Clinical Value of Percepta and Envisia Classifiers to Improve Diagnosis of Serious Lung Diseases Business Wire
03:26PM	Scaling Up Output of a Covid Vaccine Is Costly, Says Moderna Barrons.com
08:15AM	Veracyte Announces Positive Clinical Utility Data for Percepta Classifier Published in CHEST Business Wire
Aug-04-20 07:27PM	Veracyte Announces Pricing of Public Offering of 6,000,000 Shares of Common Stock Business Wire -8.75%
Aug-03-20 04:10PM	Veracyte Announces Proposed Public Offering of Common Stock Business Wire
Aug-02-20 10:53AM	What Can We Learn About Veracyte's (NASDAQ:VCYT) CEO Compensation? Simply Wall St.
Jul-30-20 07:10PM	Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates Zacks +10.04%
04:05PM	Veracyte Announces Second Quarter 2020 Financial Results Business Wire
08:15AM	Veracyte Announces Data Published in AJRCCM Showing That the Envisia Genomic Classifier Improves Physicians Ability to Diagnose IPF Without Surgery Business Wire
Jul-29-20 08:15AM	Veracyte and MAVIDx Announce Agreement for MAVIDx to Develop Ultra-High Volume COVID-19 Testing on the nCounter System Business Wire +6.19%
Jul-27-20 08:15AM	Veracyte Appoints Jens Holstein to Board of Directors and James (Jim) Erlinger as Executive Vice President, General Counsel and Secretary Business Wire
Jul-23-20 12:33PM	Analysts Estimate Veracyte (VCYT) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-16-20 07:21PM	Veracyte Clears Technical Benchmark, Hitting 80-Plus RS Rating Investor's Business Daily
08:15AM	Veracyte to Release Second Quarter 2020 Financial Results on July 30, 2020 Business Wire
Jul-05-20 05:06PM	Is Veracyte Inc (VCYT) A Good Stock To Buy? Insider Monkey
Jun-29-20 02:06PM	Race for a COVID-19 vaccine has drug makers scaling up manufacturing before one is developed MarketWatch +6.03%
Jun-11-20 08:23AM	Moderna Will Start Testing Its Covid-19 Vaccine on 30,000 People in July Barrons.com -10.51%
07:30AM	Veracyte Announces Clinical Utility Study Published in CHEST Demonstrates Envisia Genomic Classifiers Ability to Improve IPF Diagnosis Business Wire
Jun-09-20 08:15AM	Veracyte Announces De Novo Classification Request to FDA for the nCounter Dx LymphMark Assay Business Wire
Jun-04-20 05:00PM	Edited Transcript of VCYT earnings conference call or presentation 6-May-20 9:00pm GMT Thomson Reuters StreetEvents
May-27-20 08:15AM	Veracyte to Present at the William Blair 40th Annual Growth Stock Conference Business Wire
May-22-20 06:22PM	Veracyte Earns Relative Strength Rating Upgrade To 80 Investor's Business Daily
07:29AM	Everything you need to know about the Oxford University vaccine and other efforts to beat coronavirus MarketWatch
May-21-20 08:15AM	Veracyte to Present at the Jefferies Virtual Healthcare Conference Business Wire
May-18-20 03:42PM	Coronavirus update: Moderna targets vaccine approval by year's end as reopenings continue Yahoo Finance
08:25AM	Lonza Group shares climb on positive Moderna vaccine trial MarketWatch
May-14-20 08:15AM	CareDx and Veracyte Announce Exclusive Partnership for Transplant Rejection Testing on nCounter System Business Wire -6.46%
May-07-20 04:05PM	Veracyte to Present at the UBS Virtual Global Healthcare Conference Business Wire
09:31AM	Veracyte (VCYT) Q1 2020 Earnings Call Transcript Motley Fool
May-06-20 07:05PM	Veracyte (VCYT) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:05PM	Veracyte Announces First Quarter 2020 Financial Results Business Wire
03:00PM	Veracyte, Inc. to Host Earnings Call ACCESSWIRE
May-01-20 08:15AM	Veracyte Launches "More About You" Campaign to Educate Patients About Thyroid Cancer Diagnosis Business Wire
Apr-29-20 12:34PM	Veracyte (VCYT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release Zacks +7.86%
Apr-23-20 01:07PM	CORRECTING and REPLACING Veracyte and Yale Announce Exclusive License to Advance First Genomic Monitoring Test for Idiopathic Pulmonary Fibrosis Business Wire
Apr-17-20 07:35AM	The Daily Biotech Pulse: Moderna Secures $483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement Benzinga
Apr-16-20 04:30PM	Veracyte Announces Preliminary First Quarter 2020 Financial Results and Provides Business Update in Response to COVID-19 Pandemic Business Wire
Apr-13-20 10:54AM	Why Veracyte (VCYT) Stock Might be a Great Pick Zacks
Apr-08-20 07:00PM	Stock Upgrades: Veracyte Shows Rising Relative Strength Investor's Business Daily
Apr-07-20 08:15AM	Veracyte Names Tracy Morris as Vice President of Corporate Communications and Investor Relations Business Wire +6.32%
Apr-02-20 08:38AM	Veracyte, Inc. (NASDAQ:VCYT): When Will It Breakeven? Simply Wall St.
Apr-01-20 08:15AM	Veracyte Announces Novel Gene Fusion Detection with the Afirma Xpression Atlas, Which May Inform Targeted Treatment Decisions for Thyroid Cancer Patients Business Wire -16.58%
Mar-10-20 03:18AM	Edited Transcript of VCYT earnings conference call or presentation 25-Feb-20 10:00pm GMT Thomson Reuters StreetEvents +5.65%
Mar-02-20 11:00AM	Veracyte Announces Publication of Nearly 700-Patient Study Using Prosigna Breast Cancer Test to Identify Patients Likely to Benefit from Aggressive Chemotherapy Business Wire +5.71%
Feb-26-20 10:28AM	Does Market Volatility Impact Veracyte, Inc.'s (NASDAQ:VCYT) Share Price? Simply Wall St.
Feb-25-20 06:05PM	Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates Zacks
04:05PM	Veracyte Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides 2020 Financial Outlook Business Wire
Feb-13-20 08:15AM	Veracyte to Present at the 9th Annual SVB Leerink Global Healthcare Conference Business Wire
Feb-06-20 01:30PM	Veracyte to Release Fourth Quarter and Full-Year 2019 Financial Results on February 25, 2020 Business Wire
Jan-20-20 02:44PM	Should You Worry About Veracyte, Inc.'s (NASDAQ:VCYT) CEO Pay? Simply Wall St.
Jan-08-20 08:15AM	Veracyte Announces Biopharmaceutical Collaboration with Acerta Pharma Business Wire
Dec-13-19 09:06AM	Hedge Funds Might Be Selling Veracyte Inc (VCYT), But They Are Still Bullish Insider Monkey
Dec-04-19 11:56AM	Did Business Growth Power Veracyte's (NASDAQ:VCYT) Share Price Gain of 255%? Simply Wall St. +7.94%
07:06AM	The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug Benzinga
Dec-03-19 06:05PM	Peninsula diagnostics company's overseas plans could more than triple revenue American City Business Journals
05:09PM	$50M deal could expand NanoString Technologies diagnostic test into more markets American City Business Journals
05:00PM	Veracyte Acquires Exclusive License to NanoString Diagnostics Platform, Positioning Veracyte To Expand Its Genomic Testing Business Globally Business Wire
Nov-02-19 09:30AM	Veracyte Announces New Data That Advance Understanding of Genomic Alterations Targeted by Precision Medicine Therapies for Thyroid Cancer Business Wire
Oct-31-19 04:30AM	8 Undervalued Biotech Stocks to Watch Now Investopedia
Oct-30-19 08:15AM	Veracyte Announces New Data Characterizing Genomic Alterations in Thyroid Cancer To Be Presented at 89th Annual Meeting of the American Thyroid Association Business Wire
Oct-27-19 02:00PM	Hedge Funds Have Never Been This Bullish On Veracyte Inc (VCYT) Insider Monkey
Oct-24-19 06:42AM	Edited Transcript of VCYT earnings conference call or presentation 22-Oct-19 9:00pm GMT Thomson Reuters StreetEvents -5.97%
Oct-22-19 04:15PM	Veracyte Announces Third Quarter 2019 Financial Results and Business Progress Business Wire
07:00AM	Veracyte Announces New Clinical Data Showing First-Ever Noninvasive Nasal Swab Test Can Enable Early Lung Cancer Detection and Diagnosis Business Wire
Oct-21-19 04:15PM	Veracyte Announces Clinical Data Demonstrating Clinical Validity and Utility of Percepta Classifier in Lung Cancer Diagnosis When Bronchoscopy Results Are Inconclusive Business Wire +6.16%
09:57AM	Veracyte Announces New Data Demonstrating That Envisia Genomic Classifier Improves IPF Diagnosis Business Wire
Oct-09-19 03:14PM	Are Veracyte, Inc. (NASDAQ:VCYT) Investors Paying Above The Intrinsic Value? Simply Wall St. +5.54%
Oct-08-19 04:30PM	Veracyte to Release Third Quarter 2019 Financial Results and Business Progress on October 22, 2019 Business Wire

Veracyte, Inc. operates as a genomic diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to identify patients with benign thyroid nodules among those with indeterminate cytopathology results in order to rule out unnecessary thyroid surgery; Percepta Genomic Sequencing Classifier for lung cancer; Envisia Genomic Classifier that help physicians to differentiate idiopathic pulmonary fibrosis from other interstitial lung diseases without the need for surgery; and Prosigna Breast Cancer Prognostic Gene Signature Assay test for assessing risk of distant recurrence. It sells its products through product specialists, account managers, and medical science specialists. Veracyte, Inc. has a strategic collaboration with Johnson & Johnson Innovation and the Lung Cancer Initiative at Johnson & Johnson to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages; a research collaboration with Loxo Oncology for the development of therapies for patients with genetically defined cancers; and a collaboration with Johnson & Johnson Services, Inc. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ho Mark	Principal Accounting Officer	Jan 20	Option Exercise	5.16	52,500	270,675	71,434	Jan 21 05:29 PM
Anderson Bonnie H	Chairman and CEO	Jan 13	Option Exercise	5.61	18,541	104,015	222,297	Jan 15 05:03 PM
Anderson Bonnie H	Chairman and CEO	Jan 13	Sale	51.05	18,541	946,462	203,756	Jan 15 05:03 PM
Anderson Bonnie H	Chairman and CEO	Jan 12	Option Exercise	5.61	20,354	114,186	224,110	Jan 13 05:11 PM
Anderson Bonnie H	Chairman and CEO	Jan 12	Sale	50.20	20,354	1,021,772	203,756	Jan 13 05:11 PM
Anderson Bonnie H	Chairman and CEO	Jan 11	Option Exercise	8.59	71,105	610,741	274,861	Jan 13 05:11 PM
Anderson Bonnie H	Chairman and CEO	Jan 11	Sale	50.62	71,105	3,599,303	203,756	Jan 13 05:11 PM
GORDON KEVIN K	Director	Jan 04	Option Exercise	7.39	10,000	73,900	10,000	Jan 05 05:00 PM
GORDON KEVIN K	Director	Jan 04	Sale	48.98	10,000	489,798	0	Jan 05 05:00 PM
Anderson Bonnie H	Chairman and CEO	Dec 29	Option Exercise	3.73	31,313	116,919	203,756	Dec 30 05:54 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Dec 04	Option Exercise	11.15	13,468	150,209	92,327	Dec 04 07:42 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Dec 04	Sale	56.88	14,015	797,156	78,312	Dec 04 07:42 PM
GORDON KEVIN K	Director	Nov 12	Option Exercise	7.39	10,000	73,900	10,000	Nov 13 05:07 PM
GORDON KEVIN K	Director	Nov 12	Sale	47.11	10,000	471,138	0	Nov 13 05:07 PM
Ho Mark	Principal Accounting Officer	Nov 11	Sale	45.00	13,875	624,375	19,086	Nov 13 05:04 PM
Anderson Bonnie H	Chairman and CEO	Nov 10	Option Exercise	8.86	20,000	177,200	240,231	Nov 12 05:12 PM
Hanna John Walter JR	Chief Commercial Officer	Nov 06	Option Exercise	20.21	21,250	429,463	95,559	Nov 09 04:48 PM
Hanna John Walter JR	Chief Commercial Officer	Nov 06	Sale	43.44	21,250	923,106	74,309	Nov 09 04:48 PM
Hanna John Walter JR	Chief Commercial Officer	Nov 05	Option Exercise	7.48	6,406	47,902	80,715	Nov 06 04:10 PM
Hanna John Walter JR	Chief Commercial Officer	Nov 05	Sale	40.69	6,406	260,651	74,309	Nov 06 04:10 PM
Ho Mark	Principal Accounting Officer	Oct 20	Option Exercise	6.45	7,500	48,375	32,961	Oct 21 06:22 PM
Cohen Fred E	Director	Oct 19	Option Exercise	7.60	10,000	76,000	10,000	Oct 20 05:40 PM
Anderson Bonnie H	Chairman and CEO	Oct 08	Option Exercise	8.86	50,000	443,000	270,231	Oct 09 05:07 PM
Anderson Bonnie H	Chairman and CEO	Oct 08	Sale	38.00	50,000	1,900,000	220,231	Oct 09 05:07 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Oct 06	Option Exercise	20.21	2,500	50,525	81,899	Oct 07 05:06 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Oct 06	Sale	35.21	2,500	88,025	79,399	Oct 07 05:06 PM
Anderson Bonnie H	Chairman and CEO	Sep 10	Option Exercise	8.86	20,000	177,200	240,231	Sep 14 05:11 PM
Anderson Bonnie H	Chairman and CEO	Sep 10	Sale	30.89	20,000	617,861	220,231	Sep 14 05:11 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Sep 04	Option Exercise	7.66	6,479	49,618	86,426	Sep 08 05:54 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Sep 04	Sale	31.10	7,027	218,564	79,399	Sep 08 05:54 PM
Hanna John Walter JR	Chief Commercial Officer	Aug 31	Option Exercise	8.43	56,443	475,978	131,077	Sep 01 05:08 PM
Hanna John Walter JR	Chief Commercial Officer	Aug 31	Sale	33.37	56,443	1,883,550	74,634	Sep 01 05:08 PM
Hanna John Walter JR	Chief Commercial Officer	Aug 21	Option Exercise	8.86	1,400	12,404	76,034	Aug 25 05:10 PM
Hanna John Walter JR	Chief Commercial Officer	Aug 21	Sale	36.00	1,400	50,405	74,634	Aug 25 05:10 PM
Anderson Bonnie H	Chairman and CEO	Aug 10	Option Exercise	8.86	20,000	177,200	242,207	Aug 12 06:37 PM
JONES EVAN/ FA	Director	Aug 03	Sale	35.16	20,000	703,117	69,653	Aug 04 07:59 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Jul 31	Option Exercise	20.21	20,000	404,200	100,487	Aug 04 08:05 PM
Hanna John Walter JR	Chief Commercial Officer	Jul 31	Option Exercise	8.86	14,095	124,882	88,729	Aug 04 08:11 PM
Hanna John Walter JR	Chief Commercial Officer	Jul 31	Sale	36.12	14,095	509,145	74,634	Aug 04 08:11 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Jul 31	Sale	35.33	20,000	706,694	80,487	Aug 04 08:05 PM
JONES EVAN/ FA	Director	Jul 31	Sale	35.67	20,000	713,306	89,653	Aug 04 07:59 PM
Anderson Bonnie H	Chairman and CEO	Jul 30	Option Exercise	8.86	11,365	100,694	283,572	Jul 31 04:32 PM
Anderson Bonnie H	Chairman and CEO	Jul 30	Sale	32.24	11,365	366,399	272,207	Jul 31 04:32 PM
Anderson Bonnie H	Chairman and CEO	Jul 23	Option Exercise	8.86	3,280	29,061	275,487	Jul 27 05:04 PM
Anderson Bonnie H	Chairman and CEO	Jul 23	Sale	32.04	3,280	105,106	272,207	Jul 27 05:04 PM
Anderson Bonnie H	Chairman and CEO	Jul 22	Option Exercise	8.86	100	886	272,307	Jul 22 06:09 PM
Anderson Bonnie H	Chairman and CEO	Jul 22	Sale	32.00	100	3,200	272,207	Jul 22 06:09 PM
Anderson Bonnie H	Chairman and CEO	Jul 21	Option Exercise	8.86	3,447	30,540	275,654	Jul 22 06:09 PM
Hanna John Walter JR	Chief Commercial Officer	Jul 21	Option Exercise	2.40	653	1,567	75,177	Jul 22 06:16 PM
Hanna John Walter JR	Chief Commercial Officer	Jul 21	Sale	32.36	653	21,131	74,524	Jul 22 06:16 PM
Anderson Bonnie H	Chairman and CEO	Jul 21	Sale	32.09	3,447	110,614	272,207	Jul 22 06:09 PM
Anderson Bonnie H	Chairman and CEO	Jul 20	Option Exercise	8.42	20,349	171,287	292,556	Jul 22 06:09 PM
Hanna John Walter JR	Chief Commercial Officer	Jul 20	Option Exercise	2.40	11,294	27,106	85,818	Jul 22 06:16 PM
Hanna John Walter JR	Chief Commercial Officer	Jul 20	Sale	32.05	11,294	361,993	74,524	Jul 22 06:16 PM
Anderson Bonnie H	Chairman and CEO	Jul 20	Sale	32.04	20,349	651,911	272,207	Jul 22 06:09 PM
JONES EVAN/ FA	Director	Jul 15	Sale	30.12	10,000	301,192	109,653	Jul 16 05:15 PM
JONES EVAN/ FA	Director	Jul 14	Sale	28.34	20,000	566,847	119,653	Jul 16 05:15 PM
EPSTEIN ROBERT S	Director	Jul 13	Option Exercise	5.28	10,000	52,800	10,000	Jul 14 08:26 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Jul 13	Option Exercise	13.05	16,738	218,373	97,225	Jul 14 08:29 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Jul 13	Sale	29.66	16,738	496,478	80,487	Jul 14 08:29 PM
EPSTEIN ROBERT S	Director	Jul 13	Sale	29.73	10,000	297,252	0	Jul 14 08:26 PM
Kennedy Keith	COO / CFO	Jul 06	Option Exercise	7.67	47,658	365,351	200,309	Jul 07 05:47 PM
Kennedy Keith	COO / CFO	Jul 06	Sale	28.21	80,677	2,276,172	119,632	Jul 07 05:47 PM
Kennedy Keith	COO / CFO	Jul 02	Option Exercise	5.98	2,800	16,744	158,398	Jul 07 05:47 PM
Kennedy Keith	COO / CFO	Jul 02	Sale	28.02	5,747	161,040	152,651	Jul 07 05:47 PM
Anderson Bonnie H	Chairman and CEO	Jun 10	Option Exercise	4.00	20,000	80,000	292,207	Jun 11 07:06 PM
Anderson Bonnie H	Chairman and CEO	Jun 10	Sale	26.56	20,000	531,260	272,207	Jun 11 07:06 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Jun 03	Option Exercise	7.54	10,239	77,251	91,273	Jun 04 04:16 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Jun 03	Sale	26.22	10,786	282,809	80,487	Jun 04 04:16 PM
Cohen Fred E	Director	May 18	Sale	26.86	40,000	1,074,555	0	May 19 04:04 PM
Anderson Bonnie H	Chairman and CEO	May 11	Option Exercise	4.00	20,000	80,000	294,183	May 13 04:47 PM
Anderson Bonnie H	Chairman and CEO	May 11	Sale	26.67	20,000	533,334	274,183	May 13 04:47 PM
Anderson Bonnie H	Chairman and CEO	Mar 20	Option Exercise	2.68	16,000	42,880	272,313	Mar 23 05:01 PM
Anderson Bonnie H	Chairman and CEO	Mar 10	Option Exercise	4.00	20,000	80,000	276,313	Mar 11 05:05 PM
Anderson Bonnie H	Chairman and CEO	Mar 10	Sale	25.18	20,000	503,520	256,313	Mar 11 05:05 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Mar 03	Option Exercise	7.13	15,033	107,111	114,155	Mar 04 05:49 PM
Kennedy Giulia C	Chief Scientific & Med Officer	Mar 03	Sale	25.39	32,881	834,798	81,274	Mar 04 05:49 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience